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Abstract
Liver transplantation is the therapy of choice for patients with end-stage 
liver disease. However, a shortage of donor organs remains a major obstacle to 
the widespread application of liver transplantation. To overcome this problem, 
transplant centers have developed strategies to expand the organ donor pool, 
including the routine use of sub-optimal donor livers. However, these have an 
increased risk of initial poor function or primary non-function that may cause 
greater risk of morbidity in the recipient. This chapter aims to describe the 
pathophysiological changes that may occur in sub-optimal donor livers, focusing 
on viral infections, since, after transplantation, infection of the graft is almost 
universal and can lead to chronic hepatitis, cirrhosis, and graft failure. The dif-
ferent experimental models as well as the clinical outcomes of the transplantation 
of sub-optimal donor livers with viral infections will be discussed. Such informa-
tion may be useful to guide the design of better experimental models than those 
described to date as well as the effective use of sub-optimal livers with successful 
clinical application.
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1. Introduction
End-stage liver disease is associated with high morbidity and mortality, and the 
only cure is orthotopic liver transplantation (LT). The number of people awaiting 
LT continues to increase [1] and exceeds the number of available grafts. Between 
20 and 30% of patients waiting for LT will die on the waiting list or are delisted 
because of disease progression [2]. The large imbalance between the growing pool 
of potential LT recipients and the scarcity of donor organs has led to efforts to 
maximize the number of existing donors and identify possible new donors based 
on the use of liver grafts that are currently considered unsuitable for transplant due 
to their pathological condition [3]. To expand the potential donor pool, the clinical 
and scientific community is continually modifying the criteria for an acceptable 
liver donor and is turning to marginal or extended-criteria donors to meet waiting 
list demands [4]. Thus organs infected with hepatitis B (HBV) or C virus (HCV) 
are increasingly being used [5], although the risk to recipients of using such grafts 
remains unclear [6].
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Over 2 billion people across the world have serological evidence of present or 
past infection with HBV and more than 350 million individuals are estimated to be 
chronically infected [7]. It is estimated that 2–15% of liver donors are anti-hepatitis 
B core antigen (anti-HBc) positive. The proportion of positive anti-HBc livers in 
donors aged 60 years or over may rise to as much as 25% [8, 9]. Acquisition of HBV 
remains a concern after LT because the majority of infections occur via transmis-
sion by the donor liver [10], but some donors with past exposure to HBV infection 
can be used selectively in some recipients [3].
HCV is the most common indication for LT, and at current it accounts for 40–50% 
of individuals on waiting lists [11–13]. About 5% of all potential organ donors 
are positive for HCV [14]. To date, one of the most controversial issues regard-
ing extended-criteria donors has revolved around the potential positive impact of 
HCV-infected donors on short-term outcomes [15]. In Europe, the prevalence of 
anti-HBc-positive grafts reaches as much as 10% in some regions [5, 9, 16]. A multi-
variate analysis of the United Network for Organ Sharing database revealed that the 
use of anti-HBc-positive grafts is not an independent determinant of graft or patient 
survival [17]. There is a trend towards increasing the use of HCV-positive donors [18]. 
One-year patient survival rates of 97% have been reported in recipients of HCV-
infected livers compared with rates of 87% for recipients of organs meeting the 
United Network for Organ Sharing-approved criteria, with no differences in surgical 
conditions including warm and cold ischemia times between the two groups [19].
A significant number of organ donors have viral infections and the effect of 
using such organs is an important and timely question. In this chapter we describe 
the pathophysiological changes in sub-optimal donor livers with viral infections. 
In addition, post-operative outcomes after LT using sub-optimal donor livers with 
viral infections will be discussed. Therefore, I/R injury, hepatic inflammation and 
the different treatments used in recipients of donor livers with viral infections will 
be reviewed. Finally, we give details of the different experimental models of LT 
with viral infections. All of this may be useful to guide the design of appropriate 
experimental models of LT that resemble clinical conditions as much as possible, 
together with addressing the effective use of sub-optimal livers for transplant and 
the development of new protective strategies in the clinical setting of LT.
2. Sub-optimal donor and fibrosis progression
Many studies have reported the transmission of HBV from liver allografts of 
hepatitis B surface antigen (HBsAg)-negative, anti-HBc-positive donors [10, 20–28]. 
HBV within hepatocytes and passenger leukocytes in the anti-HBc allograft can be 
the source of infection in the HBsAg recipient [29]. It has been shown that employ-
ing liver grafts from these donors can transmit HBV infections to HBsAg-negative 
recipients and result in de novo hepatitis B at rates that are estimated to vary from 33 
to 78% after LT in the absence of antiviral prophylaxis [8, 10, 21]. Similarly, there are 
many reports of the presence of occult HBV infection in HBsAg/anti-HBc donors. 
Meanwhile, detectable quantities of HBV DNA have been found to be present in only 
5–10% of anti-HBc immunocompetent patients, irrespective of their anti-HBs status 
[30]. The replication capacity of HBV in the anti-HBc liver allograft is significantly 
increased after LT when recipients are administered high-dose steroids [29]. Several 
molecular mechanisms have been proposed to explain increased HBV replication 
in these patients: (1) a glucocorticoid-responsive element in the HBV genome and 
stimulation of HBV-dependent transcription by glucocorticoids [31]; (2) immuno-
suppression after LT suppresses virus-specific immune responses whereby after LT 
wild-type HBV is more frequently re-selected and this can result in better replication 
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fitness of the virus; (3) mutations selected in the HBV preS region result in a cyto-
toxic HBV strain, which is associated with cholestatic hepatitis [32–34]. HBV infec-
tion leads to graft damage in most cases [8]. It has been speculated that a liver that 
already hosts occult HBV infection, as is the case in the majority of HBcAb-positive 
donors [35], is particularly liable to suffer rapidly progressive damage when infected 
by HCV when it encounters immunosuppression for LT [36]. Some studies found 
that the survival of recipients of anti-HBc livers was significantly reduced 4 years 
after LT compared with recipients of anti-HBc-negative livers [8, 10]. With a post-
LT follow-up of 2–4 years, a minority of transplant recipients developed fibrosing 
cholestatic hepatitis or cirrhosis leading to allograft failure [37].
Recurrence rates of hepatitis C, manifested by mild chronic hepatitis, fibrosis 
or cirrhosis, have been reported to be 54.55% in HCV-positive donor grafts when 
compared with 41.74% in HCV-negative grafts [38]. Marroquin [39] showed that 
patient survival at 2 years was significantly higher in HCV-positive recipients of 
HCV-positive grafts than in HCV-positive recipients of HCV-negative grafts (90 vs. 
70%). In contrast, other studies indicated that in patients with HCV-related liver 
disease, there was no significant difference in survival between patients who received 
an HCV-negative graft and those who received an HCV-negative graft [40]. Khapra 
et al. [41] suggested that patients receiving HCV-positive donor organs develop more 
fibrosis over time than those receiving HCV-negative grafts. Wang et al. [42] reported 
that recipients show progression in liver inflammation grade or fibrosis stage regard-
less of the HCV status of the donors, although a higher stage of liver inflammation 
and fibrosis was found in HCV-positive graft recipients at follow-up. Although 
histological injury in the allograft owing to HCV is exceedingly common, progression 
of HCV is variable: some individuals experience indolent disease, whereas others 
progress rapidly to cirrhosis and liver failure [43]. Recently, donor age has been 
recognized to play an important role after LT with HCV-positive grafts. Khapra et al. 
[41] reported that HCV-positive grafts aged ≥50 years showed higher rates of graft 
failure and death among HCV-positive recipients compared to HCV-negative grafts 
from donors of the same ages. In addition, HCV-positive grafts from advanced-age 
donors showed more advanced fibrosis than those from younger donors [44].
3. I/R injury and organ dysfunction
Ischemia-reperfusion (I/R) injury, a phenomenon in which cellular damage in a 
hypoxic organ is accentuated following the restoration of oxygen delivery [45–47], is a 
multifactorial process associated with organ dysfunction of liver failure after LT. Early 
graft dysfunction affects up to 22% of liver allografts, with up to 6% of patients devel-
oping primary graft non-function and requiring retransplantation [48]. The associa-
tion of I/R injury with the severity of HCV has been reported by several authors but 
with conflicting results, since I/R may or may not influence virus recurrence [49]. 
Although I/R injury is the underlying cause of graft dysfunction in marginal organs 
[4], it remains an unexplored issue in HBV and HCV grafts from donors.
The process of organ harvesting, cold storage and reperfusion is itself damag-
ing, causing significant oxidative injury that can result in primary nonfunction or 
increase immunogenicity, prejudicing long-term graft survival [50, 51]. The duration 
of ischemic rewarming during implantation surgery is a risk factor for the severity 
of recurrent HCV disease after LT. In patients with hepatitis submitted to LT, the cal-
culated risk for recurrent HCV disease post-LT is 19% if the ischemic time is 30 min 
versus 65% if this time extends to 90 min [52]. Rewarming ischemic injury appears to 
cause severe injury that enhances reinfection of the allograft with HCV after reperfu-
sion, eventually leading to hepatic fibrosis and cirrhosis in some patients. Conversely, 
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it has also been reported that cold ischemia time was not a significant risk factor for 
recurrent HCV infection after LT [53]. Indeed, the authors indicated that rewarming 
duration during implantation of <10 min was associated with minimal recurrence, 
whereas a duration of >70 min was associated with moderate to severe recurrent 
hepatitis. This finding was supported by Velidedeoglu et al. [54] in a United Network 
for Organ Sharing database study that showed that a warm ischemia time of >90 min 
was associated with decreased graft survival in HCV-positive individuals [53].
The ischemia-reperfusion procedure itself causes apoptosis, so-called pro-
grammed cell death, in the first stages after LT [55], and it can be exacerbated 
by immunosuppressive drugs used in LT [56]. Balliardini et al. [56] mentioned 
that both hepatocellular apoptosis and cell proliferation are correlated with HCV 
infection. Sung et al. [57] suggested that HCV may also stimulate cell growth to 
counter the apoptosis and thus complete the replication cycle of HCV and produce 
infectious viral particles. Because the primary target cell for HCV replication in vivo 
is thought to be the hepatocyte, events that lead to hepatocyte proliferation may 
enhance HCV replication. Alternatively, HCV core proteins have been shown to 
interact with cellular promoters and regulators of cell growth, which may affect 
liver regeneration [58]. All these data suggest that liver regeneration associated 
with the processes associated with living related LT might affect HCV recurrence. 
Similarly, I/R injury associated with LT from brain dead donors is associated with 
apoptosis, whereas HCV is able to counteract apoptosis to increase hepatocyte 
proliferation. Further studies will be required to elucidate the effect of I/R on HCV 
recurrence as well as the effects of HCV on hepatic I/R injury associated with LT.
4. Hepatic donor inflammation in response to viral infection
The relationship between hepatocellular injury, hepatic regeneration, viral 
replicative activity, HCV antigen expression, and the pathologic host response 
remains unproven. Increased allograft damage is related to enhanced levels of 
known immune modulators, including interleukines 6 and 10. These cytokines 
are released in the milieu of injured or proliferating cells and it is known that they 
participate in the pathogenesis of HCV via increased viral activity, exaggerated 
host response, or both [59, 60]. Recurrent HCV is characterized by hepatocellular 
damage, infiltration of inflammatory cells into the liver, and tissue remodeling that 
ultimately results in progressive fibrosis and cirrhosis. Infiltrating inflammatory 
cells at the sites of liver injury secrete chemokines that stimulate hepatic stellate 
cells, these in turn proliferate and produce extracellular matrix proteins. These 
stellate cells are key players in recurrent HCV and can be activated by a number of 
stimuli in the liver transplant setting: production of ROS, secretion of cytokines 
by immune cells (acute rejection, CMV infection), hyperglycemia, and chronic 
cholestasis (biliary complications). The combination of a variety of factors explains 
the accelerated progression of fibrosis in HCV-infected liver transplant recipients 
[61]. Meanwhile, it should also be considered that the factors mentioned above are 
all generated as a consequence of hepatic I/R. Thus, it can be hypothesized that the 
mechanisms involved in hepatic I/R may exacerbate the negative post-operative 
outcomes induced by virus infection.
The mechanism by which the identified factors exert their undesirable effect 
on HCV recurrence presumably involves host-viral interactions. Since HCV is not 
directly cytopathic, HCV damage must be mediated by the host immune response. 
Both CD4- and CD8-positive T-cells participate in the recognition of HCV peptide 
displayed by infected hepatocytes [62]. In studies using an animal model of acute 
hepadnavirus infection, using woodchuck HBV, Guo et al. [63] found that viral 
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clearance occurred following the appearance of CD4 and CD8 T-cells as well as 
the production of interferon gamma and tumor necrosis factor alpha within the 
infected liver. This was accompanied by a significant increase in apoptosis and 
regeneration of hepatocytes. HCV infection initiates a specific host response that is 
ineffective at clearing virus and results in hepatic cellular damage in a nonspecific 
fashion [53, 64]. The recurrence of HCV is accelerated after LT as a result of high 
viral loads and an exaggeration of this host response, which occurs even in the pres-
ence of exogenous immunosuppression. The alloimmune response and I/R injury 
may also contribute [53, 65]. Despite the limited information on inflammation and 
post-transplant viral recurrence, there is a need for a greater understanding of the 
relationship between the virus and inflammatory processes associated with either 
I/R or virus infection by itself. This can progress to irreversible liver damage, and 
is also a relevant issue for the livers of donors infected by virus (HBV and HCV), 
which are usually in a constant inflammatory state.
5. Viral kinetics and target treatment
Despite being widely described in the literature, viral kinetics before, during 
and after LT using donor grafts with viral hepatitis has never been analyzed. The 
subject has only been considered in healthy livers transplanted into recipients with 
hepatitis. Thus investigations have mainly focused on the life cycle of the viruses 
and the recurrence of hepatitis.
Donor Therapy in recipients Effect
Before LT After LT
Anti-HBc(+) 
donors [76]
Vaccination with 
recombinant 
hepatitis B
Lamivudine Prevention of de novo HBV 
infection.
Anti-HBc(+) 
donors [77]
None HBV immune globulin 
plus
Lamivudine
Infection successfully 
managed
Survival 100%
Anti-HBc(+) 
donors [29]
HBV immune 
globulin
Lamivudine Prevention of recurrent or de 
novo infection
Anti-HBc(+) 
donors [78]
None HBV immune globulin 
plus
Lamivudine
Prevention of HBV 
transmission
Anti-HBc(+) 
donors [79]
Lamivudine or 
lamivudine plus 
adefovir
Lamivudine Prevention of infection 
development.
Anti-HBc(+) 
donors [80]
HBV immune 
globulin
HBV immune globulin 
plus
Lamivudine
Prevention of recurrent 
infection
Anti-HBc(+) 
donors [81]
HBV immune 
globulin
HBV immune 
globulin vaccination 
(recombinant)
Minimize the possibility of 
HBV recurrence
Anti-HBc(+) 
donors [82]
HBV immune 
globulin
HBV immune globulin 
plus
Lamivudine
De novo HBV reactivation 
during HBV immune globulin 
prophylaxis
Lamivudine resulted in virus 
clearance
Anti-HBc(+) 
donors [83]
HBV immune 
globulin
HBV immune globulin 
plus
Lamivudine
Prevention of HBV recurrence
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Donor Therapy in recipients Effect
Before LT After LT
Anti-HBc(+) 
donors [84]
HBV immune 
globulin
HBV immune globulin HBsAg levels became positive
HBV immune globulin 
plus Lamivudine
HBsAg-positive
HBV immune globulin 
plus lamivudine plus 
famciclovir
HBsAg-positive
Lamivudine plus 
interferon alpha
Serum HBV DNA decreased, 
but remained positive
Lamivudine plus 
adefovir
Hepatitis B e antigen status 
converted to seronegative
HCV-positive 
[85]
None DAA therapy Increases in life expectancy
HCV-positive 
[86]
None DAA therapy Prevention of HBV recurrence
HCV-positive 
[87]
None Ledipasvir and 
sofosbuvir
Prevention of HCV recurrence
LT, liver transplantation; DAA, direct-acting antivirals; HBV, hepatitis B virus; HCV, hepatitis C virus; HBc, 
hepatitis B core antigen (anti-HBc); HBsAg, hepatitis B surface antigen.
Table 1. 
Pharmacological strategies used in patient after or before the transplantation.
In patients with hepatitis undergoing LT, HCV viral load decreases during the 
anhepatic phase and after graft reperfusion because of a lack of virus production, 
blood loss, and hepatic viral clearance. Despite the decline in viral load, hepatitis C 
virions continue to circulate and rapidly infect the new graft. HCV replication in the 
liver graft begins within a few hours after LT in most patients [66], and viral load 
increases as early as 12 h after graft reperfusion. The rapid increase in HCV viral load 
indicates that viral replication is highly efficient after LT and proves the high capacity 
of HCV to adapt to a completely new environment. However, HCV kinetics did not 
follow the same pattern in all patients. Differences in the immunosuppressive regi-
men appeared to influence HCV kinetics immediately after LT [66]. In fact, HCV-
RNA concentrations increased rapidly in patients receiving corticosteroids as part 
of their immunosuppressive therapy [67–69], whereas they continued to decrease 
in most patients who were not receiving corticosteroids. Although this observation 
requires confirmation in further studies, it is possible that some immunosuppressive 
regimens might be more appropriate in the case of early antiviral therapy to eradicate 
HCV [66]. Powers et al. [70] estimated that viral resurgence begins when much less 
than 1% of the engrafted liver’s hepatocytes are infected, suggesting that antiviral 
therapy should begin soon after, or before, LT in order to prevent or delay reinfection.
Table 1 summarizes the pharmacological strategies used in patients before and 
after LT.
6. Experimental models
To the best of our knowledge, most of the current experimental models of hepa-
titis do not focus on LT. The only two experimental studies involving hepatitis and 
LT were by Dahmen et al. [71, 72], and both report severe hepatitis virus reinfection 
after woodchuck LT (Table 2). However, both studies focused on vaccines and not 
on the effects of I/R on viral infections after LT.
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7. Conclusion
A shortage of donor organs remains a major obstacle to the widespread applica-
tion of LT in patients with end-stage liver disease [73, 74]. This shortage could be 
alleviated by routine use of sub-optimal donor livers including those from donors 
with viral infections, although infection of the graft is almost universal and can lead 
to chronic hepatitis, cirrhosis, and graft failure. As stated in this chapter, studies 
on LT using sub-optimal donor grafts with viral infections have mainly focused 
on survival and the recurrence rates of hepatitis. In addition, although I/R injury 
is the underlying cause of graft dysfunction in sub-optimal donor livers with viral 
infections [4], it remains an unexplored issue in recipients transplanted with HBV 
and HCV grafts. It should be considered that the mechanisms involved in hepatic 
I/R depend on the conditions used during surgery, such as the period of ischemia 
(ranging from minutes to days) and the subclinical condition of the graft (healthy, 
sub-optimal, aged, etc.). However, clinical studies that focus on the pathological 
effects of I/R were only performed in recipients with viral infections from healthy 
liver grafts. In our view, multicenter clinical studies and experimental studies of LT 
using grafts with viral infections are needed to identify the inflammation associated 
with I/R and that induced by virus infection. The clinical application of strategies 
designed to increase the use of sub-optimal liver grafts with virus infection will 
depend on the use of experimental models of LT using donors with viral infec-
tions that resemble clinical conditions as much as possible [75]. We recognize that 
this may be difficult; however, multidisciplinary research groups should devote 
additional efforts to better understand the pathophysiology of LT using donors 
with viral infections to ultimately develop effective therapeutic strategies aimed at 
improving graft viability and at significantly increasing the organ donor pool.
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Cold 
ischemia
Anhepatic Donor Receptor Alterations after LT
<5 h <40 min WHV negative WHV 
positive
Vascular rejection
Severe vacuolar and fatty degeneration
Lymphocytic infiltrates and vacuolar 
degeneration in bile duct
Data not 
shown
Data not 
shown
WHV negative 
+ vaccine
WHV 
positive
Cholangitis was less severe
Moderate but stable jaundice
Low amounts of viral particles
WHV, woodchuck hepatitis virus.
Table 2. 
Experimental studies with hepatitis virus reinfection after liver transplantation.
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